vs
ADMA BIOLOGICS, INC.（ADMA）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是Resolute Holdings Management, Inc.的1.2倍（$139.2M vs $117.7M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -1.5%，领先36.9%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $34.6M）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
ADMA vs RHLD — 直观对比
营收规模更大
ADMA
是对方的1.2倍
$117.7M
净利率更高
ADMA
高出36.9%
-1.5%
自由现金流更多
RHLD
多$154.7M
$34.6M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $117.7M |
| 净利润 | $49.4M | $-1.7M |
| 毛利率 | 63.8% | 55.7% |
| 营业利润率 | 45.1% | 30.2% |
| 净利率 | 35.5% | -1.5% |
| 营收同比 | 18.4% | — |
| 净利润同比 | -55.9% | — |
| 每股收益（稀释后） | $0.20 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARHLD
| Q4 25 | $139.2M | $117.7M | ||
| Q3 25 | $134.2M | $120.9M | ||
| Q2 25 | $122.0M | $119.6M | ||
| Q1 25 | $114.8M | $103.9M | ||
| Q4 24 | $117.5M | — | ||
| Q3 24 | $119.8M | — | ||
| Q2 24 | $107.2M | — | ||
| Q1 24 | $81.9M | — |
净利润ADMARHLD
| Q4 25 | $49.4M | $-1.7M | ||
| Q3 25 | $36.4M | $-231.0K | ||
| Q2 25 | $34.2M | $-611.0K | ||
| Q1 25 | $26.9M | $-3.4M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | — | ||
| Q2 24 | $32.1M | — | ||
| Q1 24 | $17.8M | — |
毛利率ADMARHLD
| Q4 25 | 63.8% | 55.7% | ||
| Q3 25 | 56.3% | 59.0% | ||
| Q2 25 | 55.1% | 57.5% | ||
| Q1 25 | 53.2% | 52.5% | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMARHLD
| Q4 25 | 45.1% | 30.2% | ||
| Q3 25 | 38.0% | 34.3% | ||
| Q2 25 | 35.1% | 34.0% | ||
| Q1 25 | 30.4% | 24.7% | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | — | ||
| Q2 24 | 36.6% | — | ||
| Q1 24 | 26.7% | — |
净利率ADMARHLD
| Q4 25 | 35.5% | -1.5% | ||
| Q3 25 | 27.1% | -0.2% | ||
| Q2 25 | 28.1% | -0.5% | ||
| Q1 25 | 23.4% | -3.2% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | — | ||
| Q2 24 | 29.9% | — | ||
| Q1 24 | 21.7% | — |
每股收益（稀释后）ADMARHLD
| Q4 25 | $0.20 | $-0.20 | ||
| Q3 25 | $0.15 | $-0.03 | ||
| Q2 25 | $0.14 | $-0.07 | ||
| Q1 25 | $0.11 | $-0.39 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | — | ||
| Q1 24 | $0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $205.5M |
| 总债务越低越好 | $72.1M | $169.8M |
| 股东权益账面价值 | $477.3M | $6.5M |
| 总资产 | $624.2M | $333.4M |
| 负债/权益比越低杠杆越低 | 0.15× | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资ADMARHLD
| Q4 25 | $87.6M | $205.5M | ||
| Q3 25 | $61.4M | $148.0M | ||
| Q2 25 | $90.3M | $99.9M | ||
| Q1 25 | $71.6M | $71.0M | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
总债务ADMARHLD
| Q4 25 | $72.1M | $169.8M | ||
| Q3 25 | $72.4M | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARHLD
| Q4 25 | $477.3M | $6.5M | ||
| Q3 25 | $431.2M | $10.8M | ||
| Q2 25 | $398.3M | $9.6M | ||
| Q1 25 | $373.4M | $8.9M | ||
| Q4 24 | $349.0M | — | ||
| Q3 24 | $231.9M | — | ||
| Q2 24 | $188.3M | — | ||
| Q1 24 | $153.7M | — |
总资产ADMARHLD
| Q4 25 | $624.2M | $333.4M | ||
| Q3 25 | $568.7M | $293.2M | ||
| Q2 25 | $558.4M | $253.3M | ||
| Q1 25 | $510.6M | $214.3M | ||
| Q4 24 | $488.7M | — | ||
| Q3 24 | $390.6M | — | ||
| Q2 24 | $376.4M | — | ||
| Q1 24 | $350.9M | — |
负债/权益比ADMARHLD
| Q4 25 | 0.15× | 26.03× | ||
| Q3 25 | 0.17× | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $189.2M |
| 自由现金流率自由现金流/营收 | 24.8% | 160.8% |
| 资本支出强度资本支出/营收 | 0.8% | 5.8% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $313.2M |
8季度趋势，按日历期对齐
经营现金流ADMARHLD
| Q4 25 | $35.6M | $196.1M | ||
| Q3 25 | $13.3M | $59.6M | ||
| Q2 25 | $21.1M | $48.9M | ||
| Q1 25 | $-19.7M | $18.4M | ||
| Q4 24 | $50.2M | — | ||
| Q3 24 | $25.0M | — | ||
| Q2 24 | $45.6M | — | ||
| Q1 24 | $-2.2M | — |
自由现金流ADMARHLD
| Q4 25 | $34.6M | $189.2M | ||
| Q3 25 | $-1.1M | $58.6M | ||
| Q2 25 | $18.7M | $47.5M | ||
| Q1 25 | $-24.4M | $17.8M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
自由现金流率ADMARHLD
| Q4 25 | 24.8% | 160.8% | ||
| Q3 25 | -0.8% | 48.5% | ||
| Q2 25 | 15.3% | 39.7% | ||
| Q1 25 | -21.2% | 17.1% | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
资本支出强度ADMARHLD
| Q4 25 | 0.8% | 5.8% | ||
| Q3 25 | 10.7% | 0.8% | ||
| Q2 25 | 2.0% | 1.2% | ||
| Q1 25 | 4.1% | 0.6% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
现金转化率ADMARHLD
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RHLD
暂无分部数据
